Background: Everolimus-eluting bioresorbable vascular scaffolds (BVS), which have the
characteristics of scaffold absorption and vascular function recovery, are the latest …

Aims: Bioresorbable vascular scaffolds (BVS) have been available on the European market
since November 2011. The ASSURE registry aims to investigate the safety and efficacy of …

Objectives To identify potential differences in 2‐year outcome between patients who
underwent coronary revascularization using bioresorbable vascular scafffolds (BVS) in …

In the year of its 40th anniversary, percutaneous coronary intervention (PCI) has evolved
from balloon angioplasty over bare metal stents to drug-eluting stents (DES) and has, more …

Aim: To compare the periprocedural outcomes and patient profile of BVS and DES/BMS
implantation in an all-comer population from the ORPKI Polish National Registry. Material …

Aims: This study sought to investigate the long-term clinical outcomes related to scaffold
sizing based on quantitative coronary angiography. Methods and results: A total of 1,248 …

Background Patients with acute coronary syndrome (ACS) might represent a specific
subgroup, in which bioresorbable scaffold implantation in percutaneous coronary …

A 46-year-old male, current smoker, admitted for an inferior ST-elevation myocardial
infarction (STEMI), received thrombectomy and Absorb BVS implantation in the mid right …

The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BRS; Abbott
Vascular, Santa Clara, CA, USA) promises vascular repair maintaining lumen diameter and …

Objectives: This study sought to investigate the effect of post-dilatation on angiographic and
intracoronary imaging parameters in the setting of primary percutaneous coronary …